DHMH, Prevention and Health Promotion Administration MADAP Advisory Board

Minutes—November 10, 2016

APPROVED BY BOARD AT MAY 11, 2017 MEETING

Members Present: Letha Healey, MD, Leonard Sowah, MD, LCDR Mathilda Fienkeng, Pham D, Neha Pandit, Pham D, Janessa Smith, Pham D, Kareem Karara, Pham D, Mo Murray, Doug Rose, Daniel Hendricks, David Posner, RPh, Robyn Palmeiro, LCSW-C

Members Absent: Jeanne Keruly, CRNP, Diane Young, RN, MS, Stephanie Brooks-Wiggins, Jill Crank, RCNP, Rebecca Brotemarkle, PhD

Staff Present: Jeffrey Hitt, Onyeka Anaedozie, Mary Bahr, Arlette Lindsay, Vincent Santavenere, RPh Tanisha Carter

Recorder: Tanisha Carter

	Topic/ Issue	Discussion	Decisions Assignments/Follow-up
1.	Welcome and Introductions	Meeting was called to order by Chair, Mr. Jeffrey Hitt at 4:30 p.m. with a voting quorum present. He welcomed members and guests and introduced Tanisha Carter as the new minute's recorder and Vincent Santavenere, RPh, as MADAP's new Pharmacy Advisor. Introductions were made around the room.	
2.	Approval of the Minutes	Mr. Jeffrey Hitt asked the Board to review the May 12, 2016 minutes for any changes and/or corrections.	A few typos were identified and fixed and then Motion by David Posner, with Second by Douglas Rose, to approve the minutes as submitted. All in favor, no opposed, no abstention. Motion passed.
3.	Infectious Disease Bureau Updates	None	
4.	Client Services and MADAP Program Report	Ms. Mary Bahr, Center Chief for MADAP, reported that the majority of MADAP clients are male, 45 & older and African-American. Before ACA, 44% of clients were uninsured. As of the date of this meeting only 10% are currently uninsured. MADAP staff is preparing for Open Enrollment 2017. 1,200+ of clients are on Exchange Plans. 1,800 clients have coverage through their employer, and	
		Exchange Plans. 1,800 clients have coverage through their employer, and 1,900+ clients are on Medicare. There are 37 Exchange plans to choose from	

	Topic/ Issue	Discussion	Decisions Assignments/Follow-up
		for 2017. MADAP staff continues weekly calls with CareFirst and Exchange officials. In June 2016, HRSA conducted a comprehensive site visit with MADAP and Health Services. The ADAP expert was the Director from New York State. Based on her recommendations, MADAP will begin covering family plans as of 1-1-17 and will work to streamline the application process to make it easier for clients.	
5.	MADAP Formulary Updates	Hepatitis C medication requests Since March 2016, a total of 17 prior authorization requests were received of which 14 were approved. Of these 14, 3 clients were uninsured. Number of MADAP Clients co-infected with Hepatitis C and HIV 507 clients as of April 2015. Staff continues to ask for a cross reference with surveillance for more recent numbers.	
6.	Other Business and Announcements	Ms. Mary Bahr reported that interim approval by the Director, Mr. Jeffrey Hitt, added the following on the formulary: • Copper Intrauterine Device • Etonogestral Implant • Sofosbuvir/Velpatasvir (Epclusa) Mr. Jeffrey Hitt stated that if the contraception devices were not available through the pharmacies that he and Ms. Bahr would talk with the Bureau's Health Services Unit to figure out how to cover the costs of these devices. Mr. Jeffrey Hitt said that Epclusa, a new HCV drug, was also added to the formulary. Mr. Jeffrey Hitt asked the board for a formal recommendation to add Copper Intrauterine Device, Etonogestral Implant, and Sofosbuvir/Velpatasvir (Epclusa) to the formulary.	Motion by Morris T. Murray, with Second by Leonard Sowah, MD to recommend the addition of Copper Intrauterine Device, Etonogestral implant, and Sofosbuvir/Velpatasvir (Epclusa). All in favor, no opposed, no abstention. Motion passes.
7.	MADAP Formulary	New drugs Add Diabetic Testing Strips and Lancets to formulary and high dose Vitamin D. Discussion also covered the meters for diabetics; however, it sounded like most meters are provided to patients for free.	Motion by Letha Healey, MD, with Second by Neha Pandit, to recommend the addition of testing strips/lancets and high dose

Topic/ Issue	Discussion	Decisions Assignments/Follow-up
Activity and Review	Request to the Board has been made to add immunosuppressive medications for organ transplants (kidney, liver) to the formulary. These medications will be discussed at the next Board Meeting.	Vitamin D. All in favor, no opposed, no abstention. Motion passes.
8. Adjournment	Following a motion for adjournment, the meeting was adjourned by Director Mr. Jeffrey Hitt at 5:38 p.m.	Motion by Rose Douglas, with Second by Morris T. Murray, to adjourn the meeting.

Dates of Upcoming Advisory Board Meetings:
May 11, 2017
November 2, 2017
Meeting time: 4 – 5:30 pm

Minutes submitted by: Tanisha Carter